MCID: BLD087
MIFTS: 55

Bladder Cancer, Somatic malady

Genetic diseases (common), Cancer diseases, Nephrological diseases categories

Aliases & Classifications for Bladder Cancer, Somatic

About this section

Aliases & Descriptions for Bladder Cancer, Somatic:

Name: Bladder Cancer, Somatic 46 9 30
Bladder Cancer 46 8 64 21 44 32
Urinary Bladder Cancer 8 64 21 10
Malignant Tumor of Urinary Bladder 64 21 22
Bladder Carcinoma 30 8 44
Cancer of the Bladder 64 21
Carcinoma of Bladder 8 61
 
Malignant Neoplasm of Urinary Bladder 61
Bladder Cancer Susceptibility 46
Carcinoma of Urinary Bladder 8
Tumor of the Bladder 8
Carcinoma Bladder 8
Bladder Neoplasm 61
Bladder Tumors 44


Classifications:



Summaries for Bladder Cancer, Somatic

About this section
MedlinePlus:32 The bladder is a hollow organ in your lower abdomen that stores urine. bladder cancer occurs in the lining of the bladder. it is the sixth most common type of cancer in the united states. symptoms include blood in your urine a frequent urge to urinate pain when you urinate low back pain risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. people with a family history of bladder cancer or who are older, white, or male have a higher risk. treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. biologic therapy boosts your body's own ability to fight cancer. nih: national cancer institute

MalaCards based summary: Bladder Cancer, Somatic, also known as bladder cancer, is related to transitional cell carcinoma and costello syndrome, and has symptoms including autosomal dominant inheritanceand transitional cell carcinoma of the bladder. An important gene associated with Bladder Cancer, Somatic is FGFR3 (fibroblast growth factor receptor 3), and among its related pathways are Glioblastoma Multiforme and IL-6 Signaling Pathway. The drugs etoposide and etoposide phosphate and the compounds tetrapeptide and lovastatin have been mentioned in the context of this disorder. Related mouse phenotypes are craniofacial and skeleton.

Disease Ontology:8 A urinary bladder cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Genetics Home Reference:21 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).

Description from OMIM:46 109800

Related Diseases for Bladder Cancer, Somatic

About this section

Diseases related to Bladder Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 227)
idRelated DiseaseScoreTop Affiliating Genes
1transitional cell carcinoma30.8RB1, FGFR3
2costello syndrome30.4HRAS, KRAS
3papilloma30.4RB1, HRAS, FGFR3
4gallbladder cancer30.3HRAS, KRAS
5pancreatitis30.1KRAS, HRAS
6multiple myeloma30.0HRAS, FGFR3
7prostate cancer30.0FGFR3, RB1, KRAS
8retinoblastoma30.0FGFR3, HRAS, RB1, KRAS
9lung cancer30.0KRAS, RB1, HRAS
10breast cancer29.9KRAS, HRAS
11sarcoma29.8KRAS, RB1, HRAS
12myeloma29.8FGFR3, HRAS, RB1
13adenoma29.7KRAS, RB1, HRAS
14leukemia29.7KRAS, RB1, HRAS, FGFR3
15adenocarcinoma29.7KRAS, RB1, HRAS
16colorectal cancer29.6KRAS, HRAS, FGFR3
17melanoma29.5FGFR3, HRAS, RB1, KRAS
18prostatitis10.7
19endotheliitis10.7
20schistosomiasis10.6
21cystitis10.5
22hypoxia10.5
23superficial urinary bladder cancer10.5
24neuroendocrine carcinoma10.4
25verrucous carcinoma10.4
26hydronephrosis10.4
27inflammatory myofibroblastic tumor10.4
28amyloid tumor10.4
29large cell neuroendocrine carcinoma10.3
30rhabdoid tumor10.3
31diphtheria10.3
32tuberculosis10.3
33bladder cancer, childhood10.3
34cardiofaciocutaneous syndrome10.3KRAS
35arthritis10.3
36spinal cord injury10.3
37bacteriuria10.3
38leukemoid reaction10.3
39perivascular epithelioid cell tumor10.2
40granular cell tumor10.2
41gall bladder carcinoma in situ10.2
42orchitis10.2
43jewett-marshall bladder cancer10.2
44reactive arthritis10.2
45bladder transitional cell carcinoma10.2
46epididymo-orchitis10.2
47eosinophilic cystitis10.2
48urachal cancer10.2
49hodgkin lymphoma10.2
50urinary bladder small cell neuroendocrine carcinoma10.2

Graphical network of the top 20 diseases related to Bladder Cancer, Somatic:



Diseases related to bladder cancer, somatic

Symptoms for Bladder Cancer, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

109800

Clinical features from OMIM:

109800

HPO human phenotypes related to Bladder Cancer, Somatic:

id Description Frequency HPO Source Accession
1 autosomal dominant inheritance HP:0000006
2 transitional cell carcinoma of the bladder HP:0006740

Drugs & Therapeutics for Bladder Cancer, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Valstar13 VALRUBICIN Anthra Pharmaceuticals Approved October 1998
FDA Label: Valstar
Malady that Drug Treats: Bladder Cancer
Indications and Usage:13 VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the; urinary bladder in patients for whom immediate cystectomy would be associated with; unacceptable morbidity or mortality.
DrugBank Targets:11 1. DNA; 2. DNA topoisomerase 2-alpha
Mechanism of Action:13 
Target: DNA topoisomerase II
Action: interferes with normal breaking-resealing action
FDA: Valrubicin is an anthracycline that affects a variety of inter-related; biological functions, most of which involve nucleic acid metabolism. It readily penetrates into; cells, where it inhibits the incorporation of nucleosides into nucleic acids, causes extensive; chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to; DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference; with the normal DNA breaking-resealing action of DNA topoisomerase II.

Drug clinical trials:

Search ClinicalTrials for Bladder Cancer, Somatic

Search NIH Clinical Center for Bladder Cancer, Somatic

Inferred drug relations via UMLS61/NDF-RT40:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer, Somatic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer, Somatic:
Neo-Urinary Conduit
Embryonic/Adult Cultured Cells Related to Bladder Cancer, Somatic:
Neo-Urinary Conduit, PMID: 22136657

Genetic Tests for Bladder Cancer, Somatic

About this section

Genetic tests related to Bladder Cancer, Somatic:

id Genetic test Affiliating Genes
1 Malignant Tumor of Urinary Bladder22

Anatomical Context for Bladder Cancer, Somatic

About this section

Animal Models for Bladder Cancer, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Bladder Cancer, Somatic:

35 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.6FGFR3, HRAS, RB1, TACC3
2MP:00053908.5HRAS, RB1, TACC3, FGFR3
3MP:00053718.3TACC3, RB1, FGFR3, KRAS
4MP:00053888.2FGFR3, RB1, KRAS, HRAS
5MP:00107718.1HRAS, RB1, FGFR3, KRAS
6MP:00053978.1KRAS, TACC3, RB1, FGFR3
7MP:00036318.1RB1, KRAS, FGFR3, HRAS
8MP:00053878.0KRAS, RB1, FGFR3, TACC3
9MP:00020067.8TACC3, RB1, HRAS, FGFR3, KRAS
10MP:00028737.8KRAS, RB1, HRAS, FGFR3, TACC3
11MP:00053867.8HRAS, TACC3, KRAS, RB1, FGFR3
12MP:00053847.8KRAS, FGFR3, TACC3, RB1
13MP:00053787.7KRAS, TACC3, RB1, FGFR3, HRAS
14MP:00107687.6HRAS, RB1, FGFR3, TACC3, KRAS

Publications for Bladder Cancer, Somatic

About this section

Variations for Bladder Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer, Somatic:

63
id Symbol AA change Variation ID SNP ID
1FGFR3p.Arg248CysVAR_004148
2FGFR3p.Ser249CysVAR_004149
3FGFR3p.Gly370CysVAR_004151
4FGFR3p.Lys650GlnVAR_018390

Clinvar genetic disease variations for Bladder Cancer, Somatic:

5
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_033360.3(KRAS): c.34G> C (p.Gly12Arg)single nucleotide variantPathogenic, drug responsers121913530GRCh37Chr 12, 25398285: 25398285
2HRASNM_005343.2(HRAS): c.35G> T (p.Gly12Val)single nucleotide variantPathogenicrs104894230GRCh37Chr 11, 534288: 534288
3RB1RB1, IVS20, A-G, -2single nucleotide variantPathogenic
4FGFR3NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)single nucleotide variantPathogenicrs121913483GRCh37Chr 4, 1803568: 1803568
5FGFR3FGFR3, LYS652GLNundetermined variantPathogenic

Cosmic variations for Bladder Cancer, Somatic:

6
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1498HRASurinary tract,bladder,other,neoplasm3
2499HRASurinary tract,bladder,other,neoplasm3
3488HRASurinary tract,bladder,other,neoplasm3
4496HRASurinary tract,bladder,other,neoplasm3
5483HRASurinary tract,bladder,other,neoplasm3

Expression for genes affiliated with Bladder Cancer, Somatic

About this section
Search GEO for disease gene expression data for Bladder Cancer, Somatic.

Pathways for genes affiliated with Bladder Cancer, Somatic

About this section

Pathways related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 62)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.3HRAS, RB1
29.3RB1, HRAS
39.3RB1, HRAS
4
Show member pathways
9.3RB1, HRAS
59.3RB1, HRAS
6
Show member pathways
Prostate Cancer36
Integrated Cancer pathway36
Steroid Biosynthesis36
9.3RB1, HRAS
79.3RB1, HRAS
89.2KRAS, FGFR3
99.1HRAS, KRAS
109.1KRAS, HRAS
11
Show member pathways
9.1HRAS, KRAS
12
Show member pathways
9.1KRAS, HRAS
13
Show member pathways
9.1HRAS, KRAS
14
Show member pathways
9.1HRAS, KRAS
159.1HRAS, KRAS
169.1KRAS, HRAS
179.1HRAS, KRAS
18
Show member pathways
9.1HRAS, KRAS
199.1KRAS, HRAS
20
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
9.1KRAS, HRAS
21
Show member pathways
9.1HRAS, KRAS
22
Show member pathways
MAPK Cascade36
Immune response Oncostatin M signaling via MAPK in human cells59
Oncostatin M Signaling Pathway36
9.1KRAS, HRAS
239.1HRAS, KRAS
24
Show member pathways
9.1KRAS, HRAS
25
Show member pathways
EGFR-dependent Endothelin signaling events36
9.1KRAS, HRAS
26
Show member pathways
8.9HRAS, FGFR3, RB1
27
Show member pathways
8.9RB1, FGFR3, HRAS
28
Show member pathways
8.7HRAS, FGFR3, KRAS
29
Show member pathways
8.7KRAS, FGFR3, HRAS
30
Show member pathways
8.7HRAS, FGFR3, KRAS
31
Show member pathways
8.7HRAS, FGFR3, KRAS
32
Show member pathways
8.7KRAS, HRAS, FGFR3
33
Show member pathways
8.7FGFR3, KRAS, HRAS
34
Show member pathways
8.7HRAS, KRAS, FGFR3
35
Show member pathways
8.7KRAS, FGFR3, HRAS
36
Show member pathways
8.7FGFR3, HRAS, KRAS
37
Show member pathways
8.7KRAS, HRAS, FGFR3
38
Show member pathways
8.7FGFR3, KRAS, HRAS
398.7FGFR3, HRAS, KRAS
408.7KRAS, FGFR3, HRAS
41
Show member pathways
MAPK signaling pathway36
8.7HRAS, FGFR3, KRAS
42
Show member pathways
8.7HRAS, KRAS, FGFR3
43
Show member pathways
8.5HRAS, KRAS, RB1
44
Show member pathways
IL-9 Signaling Pathway36
Development Thrombopoietin regulated cell processes59
IL-7 Signaling Pathway36
Immune response IL 9 signaling pathway59
8.5KRAS, RB1, HRAS
458.5KRAS, RB1, HRAS
46
Show member pathways
8.5HRAS, RB1, KRAS
478.5KRAS, HRAS, RB1
48
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
8.5KRAS, RB1, HRAS
49
Show member pathways
Signaling Pathways in Glioblastoma36
8.1KRAS, RB1, HRAS, FGFR3
508.1RB1, HRAS, KRAS, FGFR3

Compounds for genes affiliated with Bladder Cancer, Somatic

About this section

Compounds related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 24)
idCompoundScoreTop Affiliating Genes
1tetrapeptide449.6RB1, HRAS
2lovastatin44 50 60 28 1113.5RB1, HRAS
3farnesyl diphosphate44 28 1111.4HRAS, KRAS
4bromodeoxyuridine449.2RB1, HRAS
5doxorubicin44 50 1111.2RB1, HRAS, FGFR3
6p002449.1KRAS, RB1
7threonine449.0HRAS, RB1, FGFR3
8cysteine448.9FGFR3, HRAS, RB1
9crcs448.9RB1, KRAS, HRAS
10paclitaxel44 50 1110.8RB1, HRAS, KRAS
11rapamycin448.8HRAS, KRAS, RB1
12ly294002448.8HRAS, KRAS, RB1
13cisplatin44 50 60 1111.8KRAS, RB1, HRAS
14h2o2448.7RB1, HRAS, KRAS
15phosphatidylinositol448.7KRAS, RB1, HRAS
16oxygen44 249.6KRAS, RB1, HRAS
17estrogen448.5KRAS, RB1, HRAS
18paraffin448.4FGFR3, KRAS, HRAS, RB1
19oligonucleotide448.4KRAS, HRAS, FGFR3, RB1
20vegf448.4FGFR3, KRAS, HRAS, RB1
21lipid448.4FGFR3, RB1, HRAS, KRAS
22tyrosine448.3RB1, FGFR3, HRAS, KRAS
23retinoic acid44 249.2KRAS, RB1, HRAS
24serine447.9FGFR3, TACC3, KRAS, HRAS, RB1

GO Terms for genes affiliated with Bladder Cancer, Somatic

About this section

Biological processes related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 28)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of smoothened signaling pathwayGO:00458799.7RB1, FGFR3
2positive regulation of MAPK cascadeGO:00434109.7HRAS, FGFR3
3positive regulation of ERK1 and ERK2 cascadeGO:00703749.6FGFR3, HRAS
4negative regulation of epithelial cell proliferationGO:00506809.6RB1, FGFR3
5mitotic cell cycle checkpointGO:00070939.6RB1, HRAS
6positive regulation of Rac protein signal transductionGO:00350229.5HRAS, KRAS
7regulation of synaptic transmission, GABAergicGO:00322289.5KRAS, HRAS
8regulation of long-term neuronal synaptic plasticityGO:00481699.5HRAS, KRAS
9social behaviorGO:00351769.4HRAS, KRAS
10visual learningGO:00085429.4HRAS, KRAS
11positive regulation of MAP kinase activityGO:00434069.4HRAS, KRAS
12activation of MAPKK activityGO:00001869.4KRAS, HRAS
13positive regulation of protein phosphorylationGO:00019349.2KRAS, HRAS
14leukocyte migrationGO:00509009.2HRAS, KRAS
15negative regulation of neuron apoptotic processGO:00435249.1HRAS, KRAS
16actin cytoskeleton organizationGO:00300369.1HRAS, KRAS
17MAPK cascadeGO:00001659.1FGFR3, HRAS, KRAS
18insulin receptor signaling pathwayGO:00082869.0HRAS, KRAS, FGFR3
19cell cycle arrestGO:00070509.0HRAS, RB1
20GTP catabolic processGO:00061849.0KRAS, HRAS
21fibroblast growth factor receptor signaling pathwayGO:00085439.0HRAS, FGFR3, KRAS
22Fc-epsilon receptor signaling pathwayGO:00380959.0KRAS, HRAS, FGFR3
23epidermal growth factor receptor signaling pathwayGO:00071739.0FGFR3, KRAS, HRAS
24neurotrophin TRK receptor signaling pathwayGO:00480119.0FGFR3, HRAS, KRAS
25positive regulation of cell proliferationGO:00082849.0KRAS, HRAS, FGFR3
26striated muscle cell differentiationGO:00511468.9KRAS, RB1, HRAS
27Ras protein signal transductionGO:00072658.9RB1, KRAS, HRAS
28innate immune responseGO:00450878.9FGFR3, HRAS, KRAS

Molecular functions related to Bladder Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00055157.5FGFR3, HRAS, RB1, TACC3, KRAS

Sources for Bladder Cancer, Somatic

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet